N. Moore
Impact in
-
- Renal cell carcinoma treatment
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Genetics top 2%
- Glioma Diagnosis and Treatment
Papers in
- Oncology 4
- HER2/EGFR in Cancer Research 3
-
- Lung Cancer Treatments and Mutations 3
- Lung Cancer Diagnosis and Treatment 2
- Renal cell carcinoma treatment 2
- Co-authors
- Natasha B. Leighl (3 shared papers)Christian Manegold (3 shared papers)Petr Zatloukal (2 shared papers)Rodryg Ramlau (2 shared papers)Jörg Michael Mezger (2 shared papers)P. Koralewski (2 shared papers)Bohuslav Melichar (2 shared papers)Christine Chevreau (2 shared papers)
- Journals
- Journal of Clinical Oncology (3 papers)The Lancet (1 paper)Annals of Oncology (1 paper)British Journal of Cancer (1 paper)Advances in Therapy (1 paper)
- Partner nations
- SwitzerlandFranceCanada
In The Last Decade
N. Moore
12 papers receiving 3.9k citations
N. Moore's Hit Papers
Peers
Comparison fields: 5 of 68
- Pulmonary and Respiratory Medicine 2.2k
- Genetics 363
- Oncology 521
- Cancer Research 176
- Molecular Biology 770
Countries citing papers authored by N. Moore
This map shows the geographic impact of N. Moore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Moore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Moore more than expected).
Fields of papers citing papers by N. Moore
This network shows the impact of papers produced by N. Moore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Moore. The network helps show where N. Moore may publish in the future.
Co-authors
The 25 scholars most cited alongside N. Moore, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Hit paper breakdown → | 2007 | 1840 |
| 2 | Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL Hit paper breakdown → | 2009 | 1247 |
| 3 | 2015 | 240 | |
| 4 | 2013 | 222 | |
| 5 | 2011 | 166 | |
| 6 | 2014 | 88 | |
| 7 | 2010 | 85 | |
| 8 | 2011 | 52 | |
| 9 | 2011 | 39 | |
| 10 | 2011 | 32 | |
| 11 | 2007 | 6 | |
| 12 | 2012 | 5 |
About N. Moore
N. Moore is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Genetics, Internal Medicine and Pathology and Forensic Medicine, having authored 12 papers that have together received 4k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (3 papers), HER2/EGFR in Cancer Research (3 papers), Lung Cancer Diagnosis and Treatment (2 papers), Glioma Diagnosis and Treatment (2 papers), Renal cell carcinoma treatment (2 papers), Venous Thromboembolism Diagnosis and Management (1 paper), Lymphoma Diagnosis and Treatment (1 paper) and Angiogenesis and VEGF in Cancer (1 paper). The work is most often cited by research in Pulmonary and Respiratory Medicine (2.2k citations), Genetics (363 citations), Oncology (521 citations), Cancer Research (176 citations) and Molecular Biology (770 citations). N. Moore has collaborated with scholars based in Switzerland, France and Canada. Frequent co-authors include Natasha B. Leighl, Christian Manegold, Petr Zatloukal, Rodryg Ramlau, Jörg Michael Mezger, P. Koralewski, Bohuslav Melichar, Christine Chevreau, Sergio Bracarda and В. А. Горбунова. Their work appears in journals such as Journal of Clinical Oncology, The Lancet, Annals of Oncology, British Journal of Cancer and Advances in Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.